INTERCEPT PHARMACEUTICALS IN's ticker is ICPT and the CUSIP is 45845P108. A total of 145 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q3 2021. The put-call ratio across all filers is 1.70 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $121,993 | +67.6% | 6,580 | 0.0% | 0.00% | – |
| Q2 2023 | $72,775 | -17.6% | 6,580 | 0.0% | 0.00% | – |
| Q1 2023 | $88,369 | +31.0% | 6,580 | +20.7% | 0.00% | – |
| Q4 2022 | $67,454 | +2.2% | 5,453 | +14.4% | 0.00% | – |
| Q3 2022 | $66,000 | 0.0% | 4,765 | 0.0% | 0.00% | – |
| Q2 2022 | $66,000 | -16.5% | 4,765 | -2.3% | 0.00% | – |
| Q1 2022 | $79,000 | +64.6% | 4,879 | +63.9% | 0.00% | – |
| Q4 2021 | $48,000 | +9.1% | 2,976 | 0.0% | 0.00% | – |
| Q3 2021 | $44,000 | -25.4% | 2,976 | 0.0% | 0.00% | – |
| Q2 2021 | $59,000 | -14.5% | 2,976 | 0.0% | 0.00% | – |
| Q1 2021 | $69,000 | -6.8% | 2,976 | 0.0% | 0.00% | – |
| Q4 2020 | $74,000 | -39.8% | 2,976 | 0.0% | 0.00% | -100.0% |
| Q3 2020 | $123,000 | -14.0% | 2,976 | 0.0% | 0.00% | 0.0% |
| Q2 2020 | $143,000 | +9.2% | 2,976 | +43.1% | 0.00% | 0.0% |
| Q1 2020 | $131,000 | -40.2% | 2,080 | +17.6% | 0.00% | -50.0% |
| Q4 2019 | $219,000 | +87.2% | 1,768 | 0.0% | 0.00% | +100.0% |
| Q3 2019 | $117,000 | +19.4% | 1,768 | +43.9% | 0.00% | 0.0% |
| Q2 2019 | $98,000 | -28.5% | 1,229 | 0.0% | 0.00% | 0.0% |
| Q1 2019 | $137,000 | -4.2% | 1,229 | -13.2% | 0.00% | 0.0% |
| Q4 2018 | $143,000 | -8.3% | 1,416 | +14.8% | 0.00% | 0.0% |
| Q3 2018 | $156,000 | +77.3% | 1,233 | +17.0% | 0.00% | 0.0% |
| Q2 2018 | $88,000 | +35.4% | 1,054 | 0.0% | 0.00% | 0.0% |
| Q1 2018 | $65,000 | +4.8% | 1,054 | 0.0% | 0.00% | 0.0% |
| Q4 2017 | $62,000 | +51.2% | 1,054 | +49.9% | 0.00% | – |
| Q3 2017 | $41,000 | -51.8% | 703 | 0.0% | 0.00% | -100.0% |
| Q2 2017 | $85,000 | -28.0% | 703 | -32.9% | 0.00% | 0.0% |
| Q1 2017 | $118,000 | +19.2% | 1,047 | +14.4% | 0.00% | 0.0% |
| Q4 2016 | $99,000 | -34.4% | 915 | 0.0% | 0.00% | -50.0% |
| Q3 2016 | $151,000 | +93.6% | 915 | +67.9% | 0.00% | +100.0% |
| Q2 2016 | $78,000 | +11.4% | 545 | 0.0% | 0.00% | 0.0% |
| Q1 2016 | $70,000 | -13.6% | 545 | 0.0% | 0.00% | 0.0% |
| Q4 2015 | $81,000 | +113.2% | 545 | +139.0% | 0.00% | 0.0% |
| Q3 2015 | $38,000 | +216.7% | 228 | +356.0% | 0.00% | – |
| Q2 2015 | $12,000 | -97.9% | 50 | -97.6% | 0.00% | -100.0% |
| Q1 2015 | $578,000 | -6.5% | 2,050 | -48.3% | 0.01% | -57.9% |
| Q4 2014 | $618,000 | -13.0% | 3,964 | +32.1% | 0.02% | -17.4% |
| Q3 2014 | $710,000 | -25.0% | 3,000 | -25.0% | 0.02% | -17.9% |
| Q2 2014 | $947,000 | – | 4,000 | – | 0.03% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Samsara BioCapital, LLC | 640,688 | $9,514,000 | 1.49% |
| CM Management, LLC | 45,000 | $668,000 | 0.50% |
| EULAV Asset Management | 660,000 | $9,801,000 | 0.26% |
| DLD Asset Management, LP | 225,200 | $3,346,000 | 0.24% |
| Virtus ETF Advisers LLC | 21,387 | $318,000 | 0.14% |
| GSA CAPITAL PARTNERS LLP | 79,145 | $1,175,000 | 0.12% |
| Hennion & Walsh Asset Management, Inc. | 136,720 | $2,030,000 | 0.11% |
| ALTRINSIC GLOBAL ADVISORS LLC | 168,800 | $2,507,000 | 0.08% |
| Inspire Investing, LLC | 31,868 | $473,000 | 0.06% |
| DUALITY ADVISERS, LP | 51,196 | $760,000 | 0.06% |